Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

NCT06026657 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Gemcitabine
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Naxitamab
BIOLOGICAL: Universal Donor Expanded TGF-beta-imprinted NK Cells

Sponsor

Margaret Gatti-Mays